​

Incyte (INCY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

INCY Stock Forecast

Incyte (INCY) stock forecast, based on 44 Wall Street analysts, predicts a 12-month average price target of $130.07, with a high of $155.00 and a low of $104.00. This represents a 3.22% increase from the last price of $126.01.

$50 $80 $110 $140 $170 $200 High: $155 Avg: $130.07 Low: $104 Last Closed Price: $126.01

INCY Stock Rating

Incyte stock's rating consensus is Buy, based on 44 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 23 Buy (52.27%), 20 Hold (45.45%), 1 Sell (2.27%), and 0 Strong Sell (0.00%).

Buy
Total 44 1 20 23 Strong Sell Sell Hold Buy Strong Buy

INCY Price Target Upside V Benchmarks

TypeNameUpside
StockIncyte3.22%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts31943
Avg Price Target$128.67$124.42$115.42
Last Closing Price$126.01$126.01$126.01
Upside/Downside2.11%-1.26%-8.40%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 26210151-28
Aug, 2629151-27
Jul, 2629141-26
Jun, 2629151128
May, 2629131126
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 20, 2026Canaccord Genuity$152.00$128.4718.32%20.63%
Aug 17, 2026Allison BratzelPiper Sandler$130.00$120.168.19%3.17%
Aug 13, 2026Bernstein$104.00$120.77-13.89%-17.47%
Aug 03, 2026Andrew BerensLeerink Partners$155.00$119.5229.69%23.01%
Jul 29, 2026Brian AbrahamsRBC Capital$109.00$126.69-13.96%-13.50%
Jul 29, 2026BMO Capital$130.00$128.830.91%3.17%
Jul 29, 2026Whitney LjemGuggenheim$150.00$129.9315.45%19.04%
Jul 29, 2026Morgan Stanley$119.00$129.93-8.41%-5.56%
Jul 29, 2026H.C. Wainwright$150.00$129.9315.45%19.04%
Jul 29, 2026Barclays$139.00$129.936.98%10.31%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 01, 2026BMO CapitalMarket PerformMarket Performhold
Aug 20, 2026BenchmarkBuyBuyhold
Aug 17, 2026Piper SandlerOverweightOverweighthold
Aug 13, 2026BernsteinMarket PerformMarket Performhold
Aug 03, 2026CitigroupBuyBuyhold
Jul 29, 2026RBC CapitalSector PerformSector Performhold
Jul 29, 2026GuggenheimBuyBuyhold
Jul 28, 2026OppenheimerOutperformOutperformhold
Jul 28, 2026OppenheimerPerformPerformhold
Jul 15, 2026CitigroupMarket PerformMarket Performhold

Financial Forecast

EPS Forecast

$0 $3 $6 $9 $12 $15 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.30$1.53$2.67$0.16$6.59---
Avg Forecast$2.58$1.76$3.60$1.26$5.90$7.18$8.78$10.69
High Forecast$2.76$1.86$3.70$1.53$6.91$9.31$11.60$11.43
Low Forecast$2.47$1.65$3.50$1.01$4.97$5.47$6.71$10.10
Surprise %66.67%-13.07%-25.83%-87.30%11.69%---

Revenue Forecast

$3B $3B $4B $5B $6B $7B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.99B$3.39B$3.70B$4.24B$5.14B---
Avg Forecast$2.92B$3.34B$3.69B$4.20B$4.64B$5.05B$5.46B$5.94B
High Forecast$3.08B$3.49B$3.73B$4.25B$4.89B$5.10B$5.52B$6.26B
Low Forecast$2.83B$3.18B$3.66B$4.13B$4.45B$5.01B$5.40B$5.70B
Surprise %2.12%1.69%0.18%0.87%10.90%---

Net Income Forecast

$0 $600M $1B $2B $2B $3B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$948.58M$340.66M$597.60M$32.62M$1.29B---
Avg Forecast$1.33B$1.45B$597.60M$287.16M$1.34B$1.26B$1.52B$2.41B
High Forecast$1.60B$1.74B$717.12M$345.89M$1.56B$2.10B$2.62B$2.58B
Low Forecast$1.07B$1.16B$478.08M$228.42M$1.12B$1.24B$1.52B$2.28B
Surprise %-28.88%-76.49%--88.64%-4.12%---

INCY Forecast FAQ

Is Incyte stock a buy?

Incyte stock has a consensus rating of Buy, based on 44 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 23 Buy, 20 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Incyte is a favorable investment for most analysts.

What is Incyte's price target?

Incyte's price target, set by 44 Wall Street analysts, averages $130.07 over the next 12 months. The price target range spans from $104 at the low end to $155 at the high end, suggesting a potential 3.22% change from the previous closing price of $126.01.

How does Incyte stock forecast compare to its benchmarks?

Incyte's stock forecast shows a 3.22% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Incyte over the past three months?

  • September 2026: 7.14% Strong Buy, 35.71% Buy, 53.57% Hold, 3.57% Sell, 0% Strong Sell.
  • August 2026: 7.41% Strong Buy, 33.33% Buy, 55.56% Hold, 3.70% Sell, 0% Strong Sell.
  • July 2026: 7.69% Strong Buy, 34.62% Buy, 53.85% Hold, 3.85% Sell, 0% Strong Sell.

What is Incyte’s EPS forecast?

Incyte's average annual EPS forecast for its fiscal year ending in December 2026 is $7.18, marking a 8.95% increase from the reported $6.59 in 2025. Estimates for the following years are $8.78 in 2027, and $10.69 in 2028.

What is Incyte’s revenue forecast?

Incyte's average annual revenue forecast for its fiscal year ending in December 2026 is $5.05B, reflecting a -1.69% decrease from the reported $5.14B in 2025. The forecast for 2027 is $5.46B, and $5.94B for 2028.

What is Incyte’s net income forecast?

Incyte's net income forecast for the fiscal year ending in December 2026 stands at $1.26B, representing a -2.14% decrease from the reported $1.29B in 2025. Projections indicate $1.52B in 2027, and $2.41B in 2028.